Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

Enanta Pharma is well positioned because FDA alignment on zelicapavir removes a major regulatory overhang and creates a clearer, more capital-efficient registrational path in RSV via a single ~200-patient Phase 2b lead-in and ~660-patient Phase 3 study. The opportunity is sizable, with management citing roughly 2.7 million potential U.S. patients across high-risk adults and pediatrics and a market opportunity approaching $2B to $2.5B annually, while prior HR3 data suggested about a seven-day symptom-resolution benefit and near-elimination of hospitalization in treated patients. In parallel, EDP-978 offers meaningful upside as a highly selective, once-daily oral KIT inhibitor with >900-fold selectivity over PDGFRα, >800-fold over PDGFRβ, and >30,000-fold over FLT3, and positive Celldex Phase 3 CSU results strengthen confidence in the mechanism ahead of 4Q26 data.

Enanta Pharma is viewed negatively because its valuation depends heavily on a DCF that already embeds a high 13.7% WACC, a 9.5x exit multiple on 2034 estimates, and only a 50% probability of success for Zelicapavir in RSV, signaling meaningful uncertainty in the core growth driver. The outlook is further weakened by the assumption of a late 2029 or early 2030 launch, which delays potential monetization while the rest of the pipeline is valued conservatively, limiting near- to medium-term upside. In addition, the company faces layered risks from clinical development, regulatory approval, commercialization, and intellectual property, while its revenue remains concentrated in royalty income rather than a diversified operating base.